Phase II trial of luspatercept with or without hydroxyurea for the treatment of patients with myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis or unclassifiable with ring sideroblasts.

被引：0
|
作者：
Mangaonkar, Abhishek Avinash
Yi, Cecilia Ysabel Arana
Murthy, Hemant S.
Badar, Talha
Foran, James M.
Geyer, Susan Michelle
McCullough, Kristen Beth
Lola, Erinayo S. Baba
Hanson, Jean
Al-Kali, Aref
Alkhateeb, Hassan B.
Shah, Mithun Vinod
Begna, Kebede
Elliott, Michelle A.
Gangat, Naseema
Litzow, Mark Robert
Wolanskyj-Spinner, Alexandra P.
Hogan, William J.
Tefferi, Ayalew
Patnaik, Mrinal
机构：
[1] Mayo Clin, Div Hematol, Rochester, MN USA
[2] Mayo Clin, Div Hematol, Scottsdale, AZ USA
[3] Mayo Clin, Jacksonville, FL USA
[4] Mayo Clin, Div Hematol, Jacksonville, FL USA
[5] Ohio State Univ, Columbus, OH USA
[6] Mayo Clin, Rochester, MN USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS7080
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Clinical analysis and literature review of a case with the myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
    Long, Bing
    Shi, Hao
    Zhu, Cuixia
    HEMATOLOGY, 2020, 25 (01) : 283 - 285
  • [22] Limited activity of luspatercept in myelofibrosis and myeloid neoplasms other than myelodysplastic syndromes with ring sideroblasts
    Gangat, Naseema
    Chetram, Deandra
    McCullough, Kristen
    Al-Kali, Aref
    Begna, Kebede
    Hogan, William
    Litzow, Mark
    Foran, James
    Badar, Talha
    Palmer, Jeanne
    Patnaik, Mrinal
    Pardanani, Animesh
    Tefferi, Ayalew
    AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 (12) : E474 - E477
  • [23] Genomic and Transcriptomic Differences of Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T) and Myelodysplastic Syndrome with Ring Sideroblasts (MDS-RS)
    Bravo, Guillermo Montalban
    Kanagal-Shamanna, Rashmi
    Darbaniyan, Faezeh
    Ganan-Gomez, Irene
    Sasaki, Koji
    Naqvi, Kiran
    Wei, Yue
    Yang, Hui
    Soltysiak, Kelly A.
    Chien, Kelly S.
    Bueso-Ramos, Carlos E.
    Kantarjian, Hagop M.
    Garcia-Manero, Guillermo
    BLOOD, 2020, 136
  • [24] Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients
    Mangaonkar, Abhishek A.
    Lasho, Terra L.
    Ketterling, Rhett P.
    Reichard, Kaaren K.
    Gangat, Naseema
    Al-Kali, Aref
    Begna, Kebede H.
    Pardanani, Animesh
    Al Ali, Najla H.
    Talati, Chetasi
    Sallman, David
    Padron, Eric
    Patnaik, Mrinal M.
    Tefferi, Ayalew
    Komrokji, Rami
    BLOOD CANCER JOURNAL, 2022, 12 (02)
  • [25] Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients
    Abhishek A. Mangaonkar
    Terra L. Lasho
    Rhett P. Ketterling
    Kaaren K. Reichard
    Naseema Gangat
    Aref Al-Kali
    Kebede H. Begna
    Animesh Pardanani
    Najla H. Al Ali
    Chetasi Talati
    David Sallman
    Eric Padron
    Mrinal M. Patnaik
    Ayalew Tefferi
    Rami Komrokji
    Blood Cancer Journal, 12
  • [26] Efficacy and Safety of Luspatercept Treatment in Patients with Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T): A Retrospective Analysis from the Medalist Study
    Komrokji, Rami S.
    Platzbecker, Uwe
    Fenaux, Pierre
    Garcia-Manero, Guillermo
    Mufti, Ghulam J.
    Santini, Valeria
    Diez-Campelo, Maria
    Finelli, Carlo
    Jurcic, Joseph G.
    Greenberg, Peter L.
    Sekeres, Mikkael A.
    Zeidan, Amer M.
    DeZern, Amy E.
    Savona, Michael R.
    Shetty, Jeevan K.
    Ito, Rodrigo
    Zhang, George
    Ha, Xianwei
    Sinsimer, Daniel
    Backstrom, Jay T.
    Verma, Amit
    BLOOD, 2020, 136
  • [27] Effects of Luspatercept on Serum Ferritin in Patients With Lower-Risk Myelodysplastic Syndromes With Ring Sideroblasts in the Phase 3 MEDALIST Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (09) : 17 - 18
  • [28] A Case of SF3B1-Positive Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis
    Lazo-Langner, Alejandro
    Sadikovic, Bekim
    TURKISH JOURNAL OF HEMATOLOGY, 2019, 36 (01) : 48 - 49
  • [29] Clinical, genomic, and transcriptomic differences between myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) and myelodysplastic syndrome with ring sideroblasts (MDS-RS)
    Montalban-Bravo, Guillermo
    Kanagal-Shamanna, Rashmi
    Darbaniyan, Faezeh
    Siddiqui, Maria Tariq
    Sasaki, Koji
    Wei, Yue
    Yang, Hui
    Chien, Kelly S.
    Naqvi, Kiran
    Jabbour, Elias
    Kadia, Tapan M.
    Daver, Naval
    DiNardo, Courtney
    Ravandi, Farhad
    Pemmaraju, Naveen
    Bose, Prithviraj
    Verstovsek, Srdan
    Pierce, Sherry
    Bueso-Ramos, Carlos
    Patel, Keyur
    Do, Kim-Anh
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    AMERICAN JOURNAL OF HEMATOLOGY, 2021, 96 (07) : E246 - E249
  • [30] Lenalidomide therapy in patients with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T)
    Nicolosi, Maura
    Mudireddy, Mythri
    Vallapureddy, Rangit
    Gangat, Naseema
    Tefferi, Ayalew
    Patnaik, Mrinal M.
    AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (01) : E27 - E30
12345